When was Neurophth founded?

Neurophth was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is Neurophth located?

Neurophth is headquartered in Wuhan, China.

How many employees does Neurophth have?

As of Jul 01, 2024, the latest employee count at Neurophth is 201 - 500.

Is Neurophth a funded company?

Neurophth is a funded company, having raised a total of $125M across 6 funding rounds to date. The company's 1st funding round was a $***** Angel round, raised on Aug 2018.

When was the latest funding round of Neurophth?

Neurophth's latest funding was a $***** Series C round on Aug 09, 2023, with participation from 6 investors. Its primary sector is Gene Therapy. In China, the Gene Therapy sector has seen $14M in funding in 2026 to date.

Where does Neurophth rank among its competitors?

Neurophth ranks 46th amongst 122 active competitors, of which 46 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Kala Pharmaceuticals, which secured $1.75M in Mar, 2026.

Who are the top competitors of Neurophth?

Neurophth's top competitors include 4D Molecular Therapeutics, Regenxbio and CureVac. Among them, Kala Pharmaceuticals secured the most recent funding round in March, 2026.

Neurophth - 2026 Company Profile, Team, Funding & Competitors

Neurophth is a series C company based in Wuhan (China), founded in 2016 by Su Xiao. It operates as a Developer of drugs for retina related diseases. Neurophth has raised $125M in funding from investors like NLVC, SDIC and HongShan. The company has 122 active competitors, including 46 funded and 25 that have exited. Its top competitors include companies like 4D Molecular Therapeutics, Regenxbio and CureVac.

Company Details

Developer of drugs for retina-related diseases. By using the AAV gene therapy platform the company has developed drugs for ophthalmic diseases. The product pipeline includes NFS-01 for Leber hereditary optic neuropathy, NFS-04 for glaucoma, NFS-05 for Dominant hereditary optic atrophy, and NFS-10 for vascular retinopathy.

Key Metrics

Founded Year

2016

Location

Wuhan, China

Stage

Series C

Total Funding

$125M in 6 rounds

Latest Funding Round

Series C, Aug 09, 2023, $*****

Investors

NLVC & 18 more

Ranked

46^th among 122 active competitors

Employee Count

201 - 500 as on Jul 01, 2024

Similar Companies

4D Molecular Therapeutics & 128 more

View Neurophth's full profile

Neurophth has raised a total funding of $125M over 6 rounds. Its first funding round was on Aug 2018. Its latest funding round was a Series C round on Aug 09, 2023 for $*****. 6 investors participated in its latest round. Neurophth has 19 institutional investors.

Here is the list of recent funding rounds of Neurophth:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 09, 2023	4281347	Series C	5208285	3239952	1664549	6348533
Apr 29, 2022	1996442	Series C	5024939	9026585	7959847	Sunshine Insurance Group & 2 more
Nov 23, 2021	4922148	Series C	6205207	8089850	CMG-SDIC Capital & 1 more	CMB International Capital & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Neurophth's funding rounds and investors

The founders of Neurophth is Su Xiao.

Here are the details of Neurophth's key team members:

Su Xiao: Co-Founder of Neurophth.

View details of Neurophth's Founder profiles and Board Members

Neurophth's employee count trend

Neurophth has 201 - 500 employees as of Jul 24. Here is Neurophth's employee count trend over the years:

Uncover Neurophth's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neurophth include 4D Molecular Therapeutics, Regenxbio and CureVac. Here is the list of Top 10 competitors of Neurophth, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	4D Molecular Therapeutics 2013, Emeryville (United States), Public	Developer of gene therapeutics for genetic disorders	$187M	Viking Global Investors, Janus Henderson Investors ... & 18 others	67/100
2nd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
3rd	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates & 16 others	67/100
4th	Kala Pharmaceuticals 2009, Waltham (United States), Public	Developer of ophthalmic treatments based on its mucosal penetrating product platform	$115M	Polaris Partners, Lux Capital & 17 others	66/100
5th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, Sanofi & 5 others	65/100
6th	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, Lincoln Park Capital & 8 others	64/100
7th	AAVantgarde Bio 2021, Milano (Italy), Series B	Developer of gene therapies using Adeno-Associated Viral vectors	$206M	Atlas Venture, Forbion & 11 others	63/100
8th	Aviceda Therapeutics 2018, Cambridge (United States), Series C	Developer of biotherapeutics for glycol-immune diseases	$255M	Omega Funds, Longitude Capital & 10 others	62/100
9th	Outlook Therapeutics 2011, Cranbury (United States), Public	Developer of antibodies for ophthalmic disorders	$51.8M	Perceptive Advisors, Armistice Capital & 12 others	61/100
10th	Complement Therapeutics 2020, London (United Kingdom), Series A	Developer of gene therapies to treat retinal diseases	$84.8M	Forbion, Gimv & 7 others	61/100
46th	Neurophth 2016, Wuhan (China), Series C	Developer of drugs for retina related diseases	$125M	NLVC, Sunshine Insurance Group & 17 others	43/100